STOCK TITAN

[Form 4] Iridex Corp Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Romeo R. Dizon, the Chief Financial Officer and a director of Iridex Corp (IRIX), reported insider purchases on 09/10/2025. He acquired 1,000 shares at $1.33 and 500 shares at $1.36, bringing his total reported beneficial ownership to 59,250 shares. The Form 4 was signed by an attorney-in-fact on 09/11/2025.

Romeo R. Dizon, Chief Financial Officer e membro del consiglio di amministrazione di Iridex Corp (IRIX), ha comunicato acquisti di insider il 10/09/2025. Ha comprato 1.000 azioni a $1,33 e 500 azioni a $1,36, portando la sua partecipazione beneficiaria totale a 59.250 azioni. Il Modulo 4 è stato firmato da un procuratore il 11/09/2025.

Romeo R. Dizon, Director Financiero y miembro del consejo de Iridex Corp (IRIX), informó compras de insider el 10/09/2025. Adquirió 1.000 acciones a $1,33 y 500 acciones a $1,36, elevando su participación beneficiaria total a 59.250 acciones. El Formulario 4 fue firmado por un apoderado el 11/09/2025.

Romeo R. Dizon은 Iridex Corp (IRIX)의 최고재무책임자이자 이사로서 2025-09-10에 내부자 매수 사실을 신고했습니다. 그는 주당 $1.33에 1,000주, 주당 $1.36에 500주를 취득하여 총 보고된 실질 보유 주식 수가 59,250주가 되었습니다. Form 4는 2025-09-11에 대리인이 서명했습니다.

Romeo R. Dizon, directeur financier et administrateur d'Iridex Corp (IRIX), a déclaré des achats d'initiés le 10/09/2025. Il a acquis 1 000 actions à 1,33 $ et 500 actions à 1,36 $, portant sa participation bénéficiaire totale à 59 250 actions. Le formulaire 4 a été signé par un mandataire le 11/09/2025.

Romeo R. Dizon, Chief Financial Officer und Direktionsmitglied von Iridex Corp (IRIX), meldete Insiderkäufe am 10.09.2025. Er erwarb 1.000 Aktien zu $1,33 und 500 Aktien zu $1,36, womit sein insgesamt gemeldeter wirtschaftlicher Besitz 59.250 Aktien beträgt. Das Formular 4 wurde am 11.09.2025 von einem Bevollmächtigten unterschrieben.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: CFO made small open-market purchases totaling 1,500 shares, a limited signal given reported ownership.

The transactions are routine open-market acquisitions at modest prices ($1.33 and $1.36) and increase the reporting persons stake to 59,250 shares. The size of the purchases is small relative to typical company market capitalization and appears unlikely to materially affect valuation or control. Disclosure is complete for the non-derivative trades reported on Form 4.

TL;DR: Insider disclosure follows Section 16 requirements; purchases reflect compliance and transparency.

The filing identifies the reporting person as CFO and director and shows timely reporting of two purchases on 09/10/2025 with a signature filed 09/11/2025 by an attorney-in-fact. From a governance perspective, the form meets reporting obligations and provides investors with updated beneficial ownership information. No derivative or unusual transactions are disclosed.

Romeo R. Dizon, Chief Financial Officer e membro del consiglio di amministrazione di Iridex Corp (IRIX), ha comunicato acquisti di insider il 10/09/2025. Ha comprato 1.000 azioni a $1,33 e 500 azioni a $1,36, portando la sua partecipazione beneficiaria totale a 59.250 azioni. Il Modulo 4 è stato firmato da un procuratore il 11/09/2025.

Romeo R. Dizon, Director Financiero y miembro del consejo de Iridex Corp (IRIX), informó compras de insider el 10/09/2025. Adquirió 1.000 acciones a $1,33 y 500 acciones a $1,36, elevando su participación beneficiaria total a 59.250 acciones. El Formulario 4 fue firmado por un apoderado el 11/09/2025.

Romeo R. Dizon은 Iridex Corp (IRIX)의 최고재무책임자이자 이사로서 2025-09-10에 내부자 매수 사실을 신고했습니다. 그는 주당 $1.33에 1,000주, 주당 $1.36에 500주를 취득하여 총 보고된 실질 보유 주식 수가 59,250주가 되었습니다. Form 4는 2025-09-11에 대리인이 서명했습니다.

Romeo R. Dizon, directeur financier et administrateur d'Iridex Corp (IRIX), a déclaré des achats d'initiés le 10/09/2025. Il a acquis 1 000 actions à 1,33 $ et 500 actions à 1,36 $, portant sa participation bénéficiaire totale à 59 250 actions. Le formulaire 4 a été signé par un mandataire le 11/09/2025.

Romeo R. Dizon, Chief Financial Officer und Direktionsmitglied von Iridex Corp (IRIX), meldete Insiderkäufe am 10.09.2025. Er erwarb 1.000 Aktien zu $1,33 und 500 Aktien zu $1,36, womit sein insgesamt gemeldeter wirtschaftlicher Besitz 59.250 Aktien beträgt. Das Formular 4 wurde am 11.09.2025 von einem Bevollmächtigten unterschrieben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dizon Romeo R

(Last) (First) (Middle)
1212 TERRA BELLA AVENUE

(Street)
MOUNTAIN VIEW CA 94043

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IRIDEX CORP [ IRIX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
09/10/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/10/2025 P 1,000 A $1.33 58,750 D
Common Stock 09/10/2025 P 500 A $1.36 59,250 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Nilo De Castro, Attorney-in-fact for Romeo R. Dizon 09/11/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Iridex

NASDAQ:IRIX

IRIX Rankings

IRIX Latest News

IRIX Latest SEC Filings

IRIX Stock Data

22.43M
12.23M
27.64%
15.83%
1.6%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
MOUNTAIN VIEW